Vol. 293, Issue 3, 829-836, June 2000

Reduction of Cisplatin Nephrotoxicity by Procainamide: Does the Formation of a Cisplatin-Procainamide Complex Play a Role?¹

Maurizio Viale, Maria Ornella Vannozzi, Ilaria Pastrone, Maria A. Mariggiò, Antonio Zicca, Angela Cadoni, Sergio Cafaggi, Giuseppina Tolino, Gianluigi Lunardi, Dario Civalleri, W. Edward Lindup and Mauro Esposito

Servizio di Farmacologia Tossicologica, Istituto Nazionale per la Ricerca sul Cancro (M.V., M.O.V., I.P., G.T., G.L., M.E.), Genova, Italy; Dipartimento di Scienze Biomediche e Oncologia Umana, Sezione di Patologia Generale, Università di Bari, Ospedale Policlinico (M.A.M.), Bari, Italy; Dipartimento di Medicina Sperimentale, Sezione di Anatomia Umana, Università di Genova (A.Z., A.C.), Genova, Italy; Dipartimento di Chimica e Tecnologie Farmaceutiche ed Alimentari, Università di Genova (S.C.), Genova, Italy; Istituto di Clinica Chirurgica I, Università di Genova (D.C.), Genova, Italy; and Department of Pharmacology and Therapeutics, University of Liverpool (W.E.L.), Liverpool, United Kingdom

Procainamide protects mice bearing P388 leukemic cells against the toxicity of cisplatin without diminishing antitumor activity. The mechanism of action of procainamide protection was investigated both in vitro and in vivo. HPLC studies showed that procainamide forms a complex with cisplatin in vitro that has a UV spectrum similar to that of DPR, a triamine platinum complex that contains procaine as ligand. We report here the effect of the reaction product of cisplatin and procainamide on both cisplatin-induced DNA interstrand cross-links (ISCLs) and on the total DNA platination of isolated DNA. Total DNA platination in vitro of isolated DNA was increased by 113% (P < .01) and 17% (P < .05) after incubation times of 1.75 and 6 h, respectively, compared with products from the reaction of cisplatin with water. Furthermore, the reaction product of cisplatin and procainamide was bound to DNA to a significantly greater extent than was cisplatin itself. ISCLs were decreased by 41% when this drug combination was incubated with DNA for 1.75 h, but no changes were observed after incubation for 6 h. We also examined the influence of the time interval between administration of cisplatin and procainamide on normal kidney injury, the renal distribution and urinary excretion of platinum, and the formation of cisplatin-DNA adducts in renal tissue of Sprague-Dawley rats after i.p. administration of 7.5 mg/kg cisplatin either with or without procainamide. The plasma concentrations of urea and creatinine and kidney histology demonstrated that procainamide provided effective protection in vivo in the rat when administered either simultaneously or at 0.5 and 1 h before or after cisplatin. The protection was accompanied by both higher renal levels of platinum and cisplatin-DNA adducts and by an increase in the formation of ISCLs. Moreover, a dose-dependent reduction of urinary excretion and concentration of platinum was also observed. We propose that procainamide, after accumulation in the kidney, may coordinate with cisplatin to form a less toxic DPR-like complex that renders rats less susceptible to cisplatin-induced toxicity.